A share price of Arcturus Therapeutics Holdings Inc [ARCT] is currently trading at $20.66, down -4.92%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ARCT shares have gain 9.02% over the last week, with a monthly amount glided 5.30%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Scotiabank started tracking the stock with Sector Outperform rating on May 28, 2025, and set its price target to $32. On January 28, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $41 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $70 on August 12, 2024. Canaccord Genuity initiated its recommendation with a Buy and recommended $90 as its price target on December 13, 2023. William Blair started tracking with a Outperform rating for this stock on July 24, 2023, and assigned it a price target of $71. In a note dated May 11, 2023, H.C. Wainwright upgraded an Buy rating on this stock and boosted its target price from $19 to $51.
Arcturus Therapeutics Holdings Inc experienced fluctuations in its stock price throughout the past year between $8.04 and $23.59. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] shares were valued at $20.66 at the most recent close of the market. An investor can expect a potential return of 108.13% based on the average ARCT price forecast.
Analyzing the ARCT fundamentals
Trailing Twelve Months sales for Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] were 109.80M which represents -46.69% decline. Gross Profit Margin for this corporation currently stands at 0.45% with Operating Profit Margin at -0.62%, Pretax Profit Margin comes in at -0.51%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.25 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.00 points at the first support level, and at 19.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.73, and for the 2nd resistance point, it is at 22.79.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] is 5.90. Further, the Quick Ratio stands at 5.90, while the Cash Ratio is 4.22. Considering the valuation of this stock, the price to sales ratio is 5.11, the price to book ratio is 2.43.
